First Tracks Biotherapeutics, Inc. (TRAX)
Nasdaq: TRAX · Pharmaceutical Preparations · filing with the SEC since 2026
Who runs First Tracks Biotherapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Faga Daniel
President, CEO. First filing Apr 2026, latest Nov 3, 2026, 0 filings in all.
Officers reporting now
4
of 10 people with a filing in the last fifteen months
Directors reporting now
6
10 people on the record since 2026
Officerssales are open-market, Nov 3, 2025 to Nov 3, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Faga Daniel | President, CEO | Apr 2026 | Nov 3, 2026 | none |
| Tamboli Ajim | Chief Financial Officer | Apr 2026 | Nov 3, 2026 | none |
| Lizzul Paul F. | Chief Medical Officer | Apr 2026 | Nov 3, 2026 | none |
| Stone Benjamin | Chief Business Officer | Apr 2026 | Nov 3, 2026 | none |
Directorssales are open-market, Nov 3, 2025 to Nov 3, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Orwin John A | director | Apr 2026 | Sep 17, 2026 | none |
| Ware J. Anthony | director | Apr 2026 | Sep 4, 2026 | 1 · $1.8M |
| Fenton Dennis M | director | Apr 2026 | Jun 17, 2026 | none |
| Jain Rita | director | Apr 2026 | Jun 17, 2026 | none |
| Marquet Magda | director | Apr 2026 | Jun 17, 2026 | none |
| Schmid John P. | director | Apr 2026 | Jun 17, 2026 | none |
Owners of more than 10% of a classsales are open-market, Nov 3, 2025 to Nov 3, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Anaptysbio, Inc | 10% owner | Apr 2026 | Apr 22, 2026 | none |
| Ecor1 Capital, LLC | 10% owner | Apr 2026 | Apr 22, 2026 | 1 · $65.0M |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.